Research Article Details
| Article ID: | A46394 |
| PMID: | 19072357 |
| Source: | Expert Rev Gastroenterol Hepatol |
| Title: | Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. |
| Abstract: | Nonalcoholic steatohepatitis is part of the broader spectrum of nonalcoholic fatty liver disease, strongly associated with insulin resistance, obesity and the metabolic syndrome. Its increasing prevalence appears to be closely related to the increased frequency of overweight or obesity; which is associated with changes in dietary habits, including an increased consumption of hypercaloric food and saturated fat, often concurrent with decreased activity and energy expenditure. Weight loss through dieting and increasing energy expenditure through the practice of regular exercise has been shown to be effective in improving nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, and is considered the mainstay of treatment. The effectiveness of these lifestyle interventions seems to rely chiefly on an improvement in insulin sensitivity. At present, disease management using a multidisciplinary team is probably pivotal for patient-centered quality of care. |
| DOI: | 10.1586/17474124.2.2.217 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |